Register a trial

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT03668119




Registration number
NCT03668119
Ethics application status
Date submitted
11/09/2018
Date registered
12/09/2018

Titles & IDs
Public title
A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)
Scientific title
A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination With Ipilimumab or Nivolumab Monotherapy in Participants With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)
Secondary ID [1] 0 0
2016-002898-35
Secondary ID [2] 0 0
CA209-848
Universal Trial Number (UTN)
Trial acronym
CheckMate 848
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Pan Tumor 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Other - Nivolumab
Treatment: Other - Ipilimumab

Experimental: Nivolumab + Ipilimumab Combination -

Experimental: Nivolumab Monotherapy -


Treatment: Other: Nivolumab
Specified dose on specified days

Treatment: Other: Ipilimumab
Specified dose on specified days
Intervention code [1] 0 0
Treatment: Other
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Objective Response Rate (ORR) Per Blinded Independent Central Review (BICR) - Arm A
Timepoint [1] 0 0
From date of randomization up to 42 months
Secondary outcome [1] 0 0
Objective Response Rate (ORR) Per Blinded Independent Central Review (BICR) - Arm B
Timepoint [1] 0 0
From date of randomization up to 57 months
Secondary outcome [2] 0 0
Objective Response Rate (ORR) Per Investigator
Timepoint [2] 0 0
From date of randomization up to 57 months
Secondary outcome [3] 0 0
Duration of Response (DoR) Per Investigator
Timepoint [3] 0 0
From date of randomization to date of first documented tumor progression, or date of death, whichever occurs first (Up to 57 months)
Secondary outcome [4] 0 0
Duration of Response (DoR) Per Blinded Independent Central Review (BICR)
Timepoint [4] 0 0
From date of randomization to date of first documented tumor progression, or date of death, whichever occurs first (Up to 57 months)
Secondary outcome [5] 0 0
Time to Objective Response (TTR) Per Investigator
Timepoint [5] 0 0
From date of randomization to date of first confirmed response (CR or PR) (Up to 57 months)
Secondary outcome [6] 0 0
Time to Objective Response (TTR) Per Blinded Independent Central Review (BICR)
Timepoint [6] 0 0
From date of randomization to date of first confirmed response (CR or PR) (Up to 57 months)
Secondary outcome [7] 0 0
Clinical Benefit Rate (CBR) Per Investigator
Timepoint [7] 0 0
From date of randomization up to 57 months
Secondary outcome [8] 0 0
Clinical Benefit Rate (CBR) Per Blinded Independent Central Review (BICR)
Timepoint [8] 0 0
From date of randomization up to 57 months
Secondary outcome [9] 0 0
Progression Free Survival (PFS) Per Investigator
Timepoint [9] 0 0
From date of randomization to date of first documented tumor progression, or date of death, whichever occurs first (Up to 57 months)
Secondary outcome [10] 0 0
Progression Free Survival (PFS) Per Blinded Independent Central Review (BICR)
Timepoint [10] 0 0
From date of randomization to date of first documented tumor progression, or date of death, whichever occurs first (Up to 57 months)
Secondary outcome [11] 0 0
Overall Survival (OS)
Timepoint [11] 0 0
From date of randomization to date of death (Up to 57 months)
Secondary outcome [12] 0 0
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Timepoint [12] 0 0
From first dose to 30 days post last dose (Up to 25 months)
Secondary outcome [13] 0 0
Number of Participants With On-Treatment Laboratory Parameters
Timepoint [13] 0 0
From first dose to 30 days post last dose (Up to 25 months)

Eligibility
Key inclusion criteria
* Participants with a refractory, metastatic, or unresectable histologically or cytologically confirmed solid malignant tumor with high tumor mutational burden (TMB-H) who are refractory to standard local therapies, or for which no standard treatment is available.
* Must be able to provide tissue and blood TMB-H testing results
* Must have measurable disease for response assessment
Minimum age
12 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Participants with melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC) or hematological malignancy as primary site of disease
* Participants who received prior treatment with an anti-programmed death-1 (anti-PD-1), anti-programmed death ligand 1 (anti-PD-L1), anti-programmed death ligand 2 (anti-PD-L2), anti-CD137, or anti-cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA-4) antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways
* Treatment with any chemotherapy, radiation therapy, biologics for cancer, or investigational therapy within 28 days of first administration of study treatment

Other protocol defined inclusion/exclusion criteria apply.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
31/10/2018
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
2/08/2023
Sample size
Target
Accrual to date
Final
212
Recruitment in Australia
Recruitment state(s)
NSW,QLD
Recruitment hospital [1] 0 0
Local Institution - 0118 - St Leonards
Recruitment hospital [2] 0 0
Local Institution - 0062 - Sydney
Recruitment hospital [3] 0 0
Local Institution - 0117 - Woolloongabba
Recruitment postcode(s) [1] 0 0
2065 - St Leonards
Recruitment postcode(s) [2] 0 0
2010 - Sydney
Recruitment postcode(s) [3] 0 0
4102 - Woolloongabba
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Colorado
Country [3] 0 0
United States of America
State/province [3] 0 0
Minnesota
Country [4] 0 0
United States of America
State/province [4] 0 0
New York
Country [5] 0 0
United States of America
State/province [5] 0 0
North Carolina
Country [6] 0 0
United States of America
State/province [6] 0 0
Oregon
Country [7] 0 0
United States of America
State/province [7] 0 0
Texas
Country [8] 0 0
Argentina
State/province [8] 0 0
Buenos Aires
Country [9] 0 0
Argentina
State/province [9] 0 0
Caba
Country [10] 0 0
Argentina
State/province [10] 0 0
Cordoba
Country [11] 0 0
Belgium
State/province [11] 0 0
Brussels
Country [12] 0 0
Belgium
State/province [12] 0 0
Bruxelles
Country [13] 0 0
Belgium
State/province [13] 0 0
Leuven
Country [14] 0 0
Canada
State/province [14] 0 0
Alberta
Country [15] 0 0
Canada
State/province [15] 0 0
Ontario
Country [16] 0 0
Canada
State/province [16] 0 0
Quebec
Country [17] 0 0
Chile
State/province [17] 0 0
Metropolitana
Country [18] 0 0
Denmark
State/province [18] 0 0
Copenhagen
Country [19] 0 0
Denmark
State/province [19] 0 0
Herlev
Country [20] 0 0
France
State/province [20] 0 0
Lyon Cedex 08
Country [21] 0 0
France
State/province [21] 0 0
Marseille Cedex 9
Country [22] 0 0
France
State/province [22] 0 0
Paris Cedex 5
Country [23] 0 0
France
State/province [23] 0 0
Toulouse
Country [24] 0 0
France
State/province [24] 0 0
Villejuif
Country [25] 0 0
Germany
State/province [25] 0 0
Berlin
Country [26] 0 0
Germany
State/province [26] 0 0
Bonn
Country [27] 0 0
Germany
State/province [27] 0 0
Dresden
Country [28] 0 0
Germany
State/province [28] 0 0
Essen
Country [29] 0 0
Germany
State/province [29] 0 0
Wuerzburg
Country [30] 0 0
Italy
State/province [30] 0 0
Genova
Country [31] 0 0
Italy
State/province [31] 0 0
Milano
Country [32] 0 0
Italy
State/province [32] 0 0
Napoli
Country [33] 0 0
Italy
State/province [33] 0 0
Siena
Country [34] 0 0
Netherlands
State/province [34] 0 0
Zuid-Holland
Country [35] 0 0
Netherlands
State/province [35] 0 0
Amsterdam
Country [36] 0 0
Poland
State/province [36] 0 0
Mazowieckie
Country [37] 0 0
Poland
State/province [37] 0 0
Gdansk
Country [38] 0 0
Puerto Rico
State/province [38] 0 0
San Juan
Country [39] 0 0
Romania
State/province [39] 0 0
Cluj
Country [40] 0 0
Romania
State/province [40] 0 0
Bucuresti
Country [41] 0 0
Romania
State/province [41] 0 0
Craiova
Country [42] 0 0
Romania
State/province [42] 0 0
Floresti
Country [43] 0 0
Romania
State/province [43] 0 0
Timisoara, Timis
Country [44] 0 0
Singapore
State/province [44] 0 0
Central Singapore
Country [45] 0 0
Singapore
State/province [45] 0 0
Singapore
Country [46] 0 0
Spain
State/province [46] 0 0
Barcelona
Country [47] 0 0
Spain
State/province [47] 0 0
Madrid
Country [48] 0 0
Spain
State/province [48] 0 0
Pamplona
Country [49] 0 0
United Kingdom
State/province [49] 0 0
Greater London
Country [50] 0 0
United Kingdom
State/province [50] 0 0
Preston

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Bristol-Myers Squibb
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Bristol-Myers Squibb
Address 0 0
Bristol-Myers Squibb
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment


What supporting documents are/will be available?




Results publications and other study-related documents

No documents have been uploaded by study researchers.


Results not provided in https://clinicaltrials.gov/study/NCT03668119